2024
Immunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
2023
Factors associated with the use of adjuvant radiation therapy in stage III melanoma
King A, Lee V, Yu B, Mirza F, Zogg C, Yang D, Tran T, Leventhal J, An Y. Factors associated with the use of adjuvant radiation therapy in stage III melanoma. Frontiers In Oncology 2023, 13: 1005930. PMID: 36816935, PMCID: PMC9929351, DOI: 10.3389/fonc.2023.1005930.Peer-Reviewed Original ResearchAdjuvant radiation therapyStage III melanomaNational Cancer Data BaseRadiation therapyPositive nodesNational Comprehensive Cancer Network guidelinesUse of RTUtilization of RTMultivariable logistic regression analysisPalliative intent therapyDistant metastatic diseasePrimary treatment modalityMajority of patientsMicroscopic residual tumorHospital-specific factorsMultivariable regression analysisLogistic regression analysisRegression analysisMetastatic diseaseOverall cohortResidual tumorDisease benefitNetwork guidelinesPalliative careMean age